AgomAb Therapeutics NV
Organization details
- Legal name
- AgomAb Therapeutics NV
- Ownership
- Public
- Status
- Active
- Sector (GICS)
- Health Care
- SIC code
- 2836 — Biological Products, (No Diagnostic Substances)
- Jurisdiction of incorporation
- Belgium
- Headquarters city
- Antwerpen
- Headquarters country
- Belgium
- Fiscal year end
- December
- Ticker symbol
- AGMB
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0002020932
Board of directors
-
Angelika Martha Jahreis · DirectorSince 2026
-
Colin Michael Bond · DirectorSince 2026
-
David R. Epstein · DirectorSince 2026
-
Marino Garcia · DirectorSince 2026
-
Naimish Patel · DirectorSince 2026
-
Ohad Hammer · DirectorSince 2026
-
Tim Jasper Knotnerus · Director · Chief Executive OfficerSince 2026
-
Weegen Felice Isabel Verduyn-van · DirectorSince 2026
Chief executives
Board connections
3 of this board's directors also sit on 3 other boards. 2 are in the same sector.
-
Dianthus Therapeutics Inc. Same sectorvia Marino Garcia
-
Evommune Inc. Same sectorvia Weegen Felice Isabel Verduyn-van
- via David R. Epstein
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $503,470
- 13 purchases by 3 insiders
- Sold, last 12 months
- $0
- 0 sales by 0 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Nov 5, 2026 | David R. Epstein Director | Open-market purchase | +5,000 | $6.81 | $34,050 |
| Nov 5, 2026 | David R. Epstein Director | Open-market purchase | +5,000 | $6.91 | $34,550 |
| Nov 5, 2026 | David R. Epstein Director | Open-market purchase | +5,000 | $6.98 | $34,900 |
| Oct 21, 2026 | David R. Epstein Director | Open-market purchase | +5,000 | $8.86 | $44,300 |
| Oct 21, 2026 | David R. Epstein Director | Open-market purchase | +5,000 | $8.90 | $44,500 |
| Oct 8, 2026 | David R. Epstein Director | Open-market purchase | +5,000 | $8.90 | $44,500 |
| Oct 6, 2026 | Kemula Pierre Thadee Victor Officer (Chief Financial Officer) | Open-market purchase | +3,000 | $8.67 | $26,010 |
| Oct 6, 2026 | David R. Epstein Director | Open-market purchase | +5,000 | $8.70 | $43,500 |
| Oct 6, 2026 | Kemula Pierre Thadee Victor Officer (Chief Financial Officer) | Open-market purchase | +5,000 | $8.57 | $42,850 |
| Oct 6, 2026 | Tim Jasper Knotnerus Director, Officer (Chief Executive Officer) | Open-market purchase | +5,000 | $8.70 | $43,500 |
| Oct 6, 2026 | Kemula Pierre Thadee Victor Officer (Chief Financial Officer) | Open-market purchase | +2,000 | $8.54 | $17,080 |
| Oct 5, 2026 | David R. Epstein Director | Open-market purchase | +5,000 | $8.57 | $42,850 |
| Oct 5, 2026 | Tim Jasper Knotnerus Director, Officer (Chief Executive Officer) | Open-market purchase | +6,000 | $8.48 | $50,880 |
Peers
Compare boardsOrganizations in the same sector, closest in location and size first.
Questions about AgomAb Therapeutics NV
Who is the CEO of AgomAb Therapeutics NV?
Tim Jasper Knotnerus has been AgomAb Therapeutics NV's Chief Executive Officer since March 2026.
How many directors are on AgomAb Therapeutics NV's board?
AgomAb Therapeutics NV's board has 8 directors: Angelika Martha Jahreis, Colin Michael Bond, David R. Epstein, Marino Garcia, Naimish Patel, Ohad Hammer, Tim Jasper Knotnerus and Weegen Felice Isabel Verduyn-van.
Are AgomAb Therapeutics NV insiders buying or selling shares?
Over the last 12 months, AgomAb Therapeutics NV insiders bought $503,470 of shares in 13 purchases and made no open-market sales on the open market, as reported to the SEC on Forms 4 and 5.
Embed this board on your site
Paste this where the board should appear. It always shows the current directors and links back here.
<div data-bod-board="agomab-therapeutics-nv"></div>
<script src="https://boardofdirectors.review/embed.js" async></script>Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.